

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Edaravone and MAPK pathway: the key role of gut permeability

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1737958> since 2020-05-04T11:06:38Z

Published version:

DOI:10.23736/S0026-4806.20.06494-0

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Edaravone and MAPK pathway: the key role of gut permeability

Gian Paolo CAVIGLIA¹

¹Department of Medical Sciences, University of Turin, Turin, Italy

Corresponding author: Gian Paolo Caviglia, Department of Medical Sciences, University of Turin,
Via Cavour 31, Turin 10100, Italy. Tel: +39 (0)11 6333922; Fax: +39 (0)11 6333976; e-mail:
gianpaolo.caviglia@unito.it

Conflict of interest statement: None to declare

Key words: Edaravone, intestinal permeability, intestinal epithelium

Dear Sir,

In a recent publication Wu *et al.* reported the results of a study, conducted in 30 Sprague-Dawley rats, evaluating the impact of edaravone, in alleviating oxidative stress and apoptosis of intestinal epithelium after burns via MPAK pathway.¹ Edaravone is a drug known to be antioxidant and it is used in some Countries (mainly Japan and US) to treat patients with stroke or amyotrophic lateral sclerosis. The authors found that its use after burns increased the activities of superoxide dismutase and catalase and reduced the activities of myeloperoxidase and malondialdehyde. Considering other parameters, down or upregulated in intestine tissue of rats treated with edaravone, the authors concluded that the latter protects from burns-induced intestinal injury.¹ This occurs modulating the complexity of processes regulated by MAPK pathway.

This study recalls the central role of gut permeability and its environment. Formed by an epithelium and a lymphocyte-rich sub-epithelium, and a lumen indwelled by billions of micro-organisms (the so-called microbiome that contains bacteria, viruses, fungi and other single-celled organisms), the gut is classified as a barrier organ. Its integrity depends on the maintenance of the sealing status of the mucosa and the submucosa. The equilibrium of the system is related to the regulation of a subliminal lingering inflammation: infections, drugs, tobacco, psychological stress are but a few of the agents that can alter the sealing status mentioned above maintaining a balance.² All perturbations of this machinery makes a continuum of severity gradient ranking from irritable bowel syndrome³ to the severest inflammatory bowel disease.⁴ Furthermore, intestinal microbiome has become a key topic in the investigation of several extra-gastrointestinal diseases.⁵ Hence, today each study on intestinal environment, in both animal model and humans, should consider the key role of intestinal permeability and microbiome.

References

1. Wu J, Zhou M, Yu X, Ma J, Wu Y. Edaravone alleviates oxidative stress and apoptosis of intestinal epithelium after burns via MAPK pathway. *Minerva Med* 2019;110:587-90.
2. Caviglia GP, Rosso C, Ribaldone DG, Dughera F, Fagoonee S, Astegiano M, *et al.* Physiopathology of intestinal barrier and the role of zonulin. *Minerva Biotechnol* 2019;31:83-92.
3. Masoodi I, Alshaqeeti AS, Ahmad S, Alyamani EJ, Al-Lehibi AA, Qutub AN, *et al.* Microbial dysbiosis in inflammatory bowel diseases: results of a metagenomic study in Saudi Arabia. *Minerva Gastroenterol Dietol* 2019;65:177-86.
4. Adriani A, Ribaldone DG, Astegiano M, Durazzo M, Saracco GM, Pellicano R. Irritable bowel syndrome: the clinical approach. *Panminerva Med* 2018;60:213-22.
5. Kobylak N, Abenavoli L, Falalyeyeva T, Mykhalchyshyn G, Boccuto L, Kononenko L, *et al.* Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study. *Minerva Med* 2018;109:418-28.